PMID- 26466016
OWN - NLM
STAT- MEDLINE
DCOM- 20160729
LR  - 20181113
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Print)
IS  - 1478-7210 (Linking)
VI  - 13
IP  - 11
DP  - 2015
TI  - Fc receptors and their influence on efficacy of therapeutic antibodies for 
      treatment of viral diseases.
PG  - 1351-60
LID - 10.1586/14787210.2015.1079127 [doi]
AB  - The lack of vaccines against several important viral diseases necessitates the 
      development of therapeutics to save lives and control epidemics. In recent years, 
      therapeutic antibodies have received considerable attention due to their good 
      safety profiles and clinical success when used against viruses such as 
      respiratory syncytial virus, Ebola virus and Hendra virus. The binding affinity 
      of these antibodies can directly impact their therapeutic efficacy. However, we 
      and others have also demonstrated that the subtype of Fc-gamma receptors (FcgammaRs) 
      engaged influences the stoichiometric requirement for virus neutralization. 
      Hence, the development of therapeutic antibodies against infectious diseases 
      should consider the FcgammaRs engaged and Fc-effector functions involved. This review 
      highlights the current state of knowledge about FcgammaRs and FcgammaR effector functions 
      involved in virus neutralization, with emphasis on factors that can affect FcgammaR 
      engagement. A better understanding of Fc-FcgammaR interactions during virus 
      neutralization will allow development of therapeutic antibodies that are 
      efficacious and can be administered with minimal side effects.
FAU - Chan, Kuan Rong
AU  - Chan KR
AD  - a 1 Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, 
      Singapore 169857, Singapore.
FAU - Ong, Eugenia Z
AU  - Ong EZ
AD  - b 2 Experimental Therapeutics Centre, Agency for Science Technology and Research, 
      31 Biopolis Way, Singapore 138669, Singapore.
FAU - Mok, Darren Z L
AU  - Mok DZ
AD  - c 3 Department of Microbiology, Yong Loo Lin School of Medicine, National 
      University of Singapore, Singapore 117597, Singapore.
FAU - Ooi, Eng Eong
AU  - Ooi EE
AD  - a 1 Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, 
      Singapore 169857, Singapore.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150824
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Neutralizing/*therapeutic use
MH  - Cytokines/immunology
MH  - Humans
MH  - Immunoglobulin G
MH  - Phagocytosis/immunology
MH  - Receptors, IgG/*metabolism
MH  - Virus Diseases/*drug therapy/prevention & control
PMC - PMC4673539
OTO - NOTNLM
OT  - Fc-effector functions
OT  - Fc-receptors
OT  - antibody
OT  - neutralization
OT  - therapeutics
EDAT- 2015/10/16 06:00
MHDA- 2016/07/30 06:00
PMCR- 2015/12/09
CRDT- 2015/10/15 06:00
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2016/07/30 06:00 [medline]
PHST- 2015/12/09 00:00 [pmc-release]
AID - 1079127 [pii]
AID - 10.1586/14787210.2015.1079127 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2015;13(11):1351-60. doi: 
      10.1586/14787210.2015.1079127. Epub 2015 Aug 24.